Ness-Ziona, Israel – With the threat of Ebola intensifying by the day, scientists worldwide are focusing on the human-cell-producing qualities of the tobacco plant in search of a vaccine. Accordingly, reps for Israel’s pioneers in synthesizing recombinant proteins from tobacco plants CollPlant say they are ready to assist in any way possible.
Subscribe to our Daily Roundup Email
TIMESOFISRAEL.com (http://bit.ly/1wtlYJW) reports that currently, a product called Zmapp, developed by San Diego’s Leaf Bio and Mapp Biopharmaceutical, is the most effective Ebola treatment to date, but CollPlant’s founder and CEO, Prof. Oded Shoseyov says that, due to CollPlant’s cutting-edge technology in mass producing human antibodies in tobacco plants, reps from both companies have been speaking “on a regular basis.”
Shoseyov said that when it comes to the process “we have taken it farther than anyone else.”
Shoseyov said CollPlant, which he started about six years ago, is standing by to be of assistance to anyone in need of help as the search for an Ebola vaccine continues, noting that he has full confidence Zmapp researchers who are seemingly at the forefront
“We know them very well,” Shoseyov said. “The community of researchers doing work in this area is very small.”
My money is on Israel to find a vaccine for ebola.